Litcius/Paper detail

Synthesis and Structure−Activity Relationships of Imidazopyridine/Pyrimidine‐ and Furopyridine‐Based Anti‐infective Agents against Trypanosomiases

Daniel Gedder Silva, Anna Junker, Shaiani Maria Gil de Melo, Fernando Fumagalli, J. Robert Gillespie, Nora M. R. Molasky, Frederick S. Buckner, An Matheeussen, Guy Caljon, Louis Maes, Flávio da Silva Emery

2020ChemMedChem28 citationsDOIOpen Access PDF

Abstract

Neglected tropical diseases remain among the most critical public health concerns in Africa and South America. The drug treatments for these diseases are limited, which invariably leads to fatal cases. Hence, there is an urgent need for new antitrypanosomal drugs. To address this issue, a large number of diverse heterocyclic compounds were prepared. Straightforward synthetic approaches tolerated pre-functionalized structures, giving rise to a structurally diverse set of analogs. We report on a set of 57 heterocyclic compounds with selective activity potential against kinetoplastid parasites. In general, 29 and 19 compounds of the total set could be defined as active against Trypanosoma cruzi and T. brucei brucei, respectively (antitrypanosomal activities <10 μM). The present work discusses the structure-activity relationships of new fused-ring scaffolds based on imidazopyridine/pyrimidine and furopyridine cores. This library of compounds shows significant potential for anti-trypanosomiases drug discovery.

Topics & Concepts

ImidazopyridinePyrimidineTrypanocidal agentDrug discoveryComputational biologyDrugStereochemistryCombinatorial chemistryChemistryStructure–activity relationshipActive compoundBiologyTrypanosoma bruceiPharmacologyBiochemistryGeneIn vitroTrypanosoma species research and implicationsResearch on Leishmaniasis StudiesSynthesis and Biological Evaluation
Synthesis and Structure−Activity Relationships of Imidazopyridine/Pyrimidine‐ and Furopyridine‐Based Anti‐infective Agents against Trypanosomiases | Litcius